Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

Peptides for Ebola Research | Ebola Peptide Pools & PepMix™

Ebola Peptides for Ebola Research Ebola Virus Disease (EVD) Ebola virus disease (EVD), also known as Ebola hemorrhagic fever, is a severe and often fatal infectious disease caused by viruses of the Ebolavirus genus within the Filoviridae family. Ebolaviruses a

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

Ebola

Peptides for Ebola Research

Ebola Virus Disease (EVD)

Ebola virus disease (EVD), also known as Ebola hemorrhagic fever, is a severe and often fatal infectious disease caused by viruses of the Ebolavirus genus within the Filoviridae family. Ebolaviruses are single-stranded RNA (ssRNA) viruses transmitted through direct contact with infected blood, body fluids, or tissues from infected humans or animals. Fruit bats are considered the most likely natural reservoir.

Since its discovery in 1976, Ebola has caused multiple outbreaks across Africa, ranging from localized epidemics to large-scale public health emergencies. Depending on the viral species and outbreak conditions, case fatality rates can range from approximately 25% to as high as 90%.

Ebolavirus research often focuses on viral proteins that are relevant for immune recognition, vaccine development, diagnostic assay design, and therapeutic antibody discovery. Peptide-based tools are especially useful for studying antigen-specific T-cell responses and identifying linear immune epitopes.

Four ebolavirus species are known to cause disease in humans:

Zaire ebolavirus (EBOV)

Sudan ebolavirus (SUDV)

Bundibugyo ebolavirus (BDBV)

Taï Forest ebolavirus (TAFV)

All ebolaviruses are classified as WHO Risk Group 4 (RG4) pathogens.

Ebola Peptide Pools for Key Ebolavirus Strains

JPT’s Ebola PepMix™ portfolio includes peptide pools for important ebolavirus strains and antigens, including Zaire Ebola GP/Mayinga-76, Bundibugyo ebolavirus GP/Uganda-07, Sudan ebolavirus GP/Uganda-00, and Taï Forest ebolavirus NP. These products support research workflows where scientists need defined synthetic peptides rather than infectious viral material.

Zaire ebolavirus (EBOV)

The Most Studied and Most Lethal Ebola Species

Zaire ebolavirus was first identified in 1976 during an outbreak in Yambuku, in what is now the Democratic Republic of the Congo (formerly Zaire), near the Ebola River from which the virus derives its name. The Zaire strain is responsible for the largest and deadliest Ebola outbreaks recorded to date, including the 2014–2016 West African epidemic. Historically, Zaire ebolavirus has shown mortality rates ranging from 60–90%, depending on outbreak conditions and healthcare access.

Today, Zaire ebolavirus represents the best-characterized of all Ebola strains used in peptide-based immune-response research::

Approved vaccines are available: The recombinant vesicular stomatitis virus vaccine (rVSV-ZEBOV / Ervebo®) is currently approved for prevention of Zaire ebolavirus disease and has significantly improved outbreak response capabilities

Monoclonal antibody therapies have been developed

Established molecular diagnostic assays exist

Extensive immunological and epitope data are available

Bundibugyo ebolavirus (BDBV)

An Emerging Challenge in Ebola Research

Bundibugyo ebolavirus was first identified in 2007 during an outbreak in the Bundibugyo district of western Uganda. Genetic analysis revealed that the virus differed significantly from previously known Ebola species and therefore constituted a new ebolavirus species.

Additional outbreaks occurred in the Democratic Republic of the Congo in 2012 and renewed attention to Bundibugyo ebolavirus has increased scientific interest in non-Zaire Ebola strains, including vaccine, therapeutic, diagnostic, and immune-monitoring research.

Compared to Zaire ebolavirus, Bundibugyo ebolavirus generally shows lower mortality rates, typically around 25–50%. However, it presents major scientific and clinical challenges:

No licensed vaccines are currently available

No approved targeted therapeutics exist

Limited diagnostic coverage compared to Zaire strains

Less immunological characterization data are available

Bundibugyo Ebola GP peptide pools can support studies of strain-specific and cross-reactive immune responses, especially where standard assays have historically focused more heavily on Zaire ebolavirus. Recent outbreaks have demonstrated how difficult Bundibugyo infections can be to detect and contain, especially when standard diagnostic workflows are optimized primarily for Zaire ebolavirus.

Sudan ebolavirus (SUDV)

Sudan ebolavirus is another major Ebola-causing virus associated with severe outbreaks in humans. Unlike Zaire ebolavirus, there is currently no broadly licensed vaccine specifically approved for Sudan ebolavirus disease, making Sudan ebolavirus an important focus for vaccine research, immune monitoring, and diagnostic assay development.

Sudan ebolavirus GP peptide pools can be used to study glycoprotein-specific T-cell responses, compare immune recognition across Ebola strains, and support research into strain-specific or pan-ebolavirus vaccine strategies.

Taï Forest ebolavirus (TAFV)

Taï Forest ebolavirus has been associated with human infection and remains relevant for comparative ebolavirus research. Although it is much less frequently reported than Zaire, Sudan, or Bundibugyo ebolaviruses, Taï Forest ebolavirus antigens can support broader studies of ebolavirus immune recognition and cross-reactivity.

Taï Forest ebolavirus NP peptide pools may be useful for studying nucleoprotein-specific immune responses and comparing conserved immune targets across different Ebola strains.

About Ebolavirus Proteins

The Ebola virus genome encodes several proteins relevant for host immune recognition and viral pathogenicity, including:

Glycoprotein (GP)

Nucleoprotein (NP)

VP24

VP30

VP35

VP40

RNA-dependent

RNA polymerase (L protein)

Peptide Research Applications

As a result of recent outbreaks, there is increasing interest in:

(Cross-reactive) vaccine and therapeutic development

Immune monitoring

Epitope mapping

Antibody profiling

T-cell response characterization

Diagnostic assay development

Broad-spectrum diagnostics

Pan-ebolavirus therapeutic strategies

JPT's Ebola Peptide Tools

Filter products

T-cell immunity

PepMix Peptide Pools

PepMix Peptide Pools Infections

Ebola

Ebola fever

Infection

Ebola Virus (ZEBOV)

Ebola virus

Envelope glycoprotein

Envelope protein

Nucleoprotein

No

PepMix™ Bundibugyo Ebolavirus (Envelope GP/Uganda-07)

US$605.80

PepMix™ Sudan Ebolavirus (GP/Uganda-00)

US$715.00

PepMix™ Tai Forest Ebolavirus (NP)

US$748.80

PepMix™ Zaire Ebola (GP/Mayinga-76)

References

CD4+ T cell-mediated immunity protects from VSV-SUD lethal challenge in a mouse model of Sudan virus infection Kelchtermans et al., Nature Immunology (2026) Product used: PepMix™ Sudan Ebolavirus (GP/Uganda-00)

Antibody-Based Antigen Delivery to Dendritic Cells as a Vaccination Strategy Against Ebola Virus Disease Olal et al., Journal of Infectious Diseases (2025) - PMID: 39852693 Product used: Custom Peptide Synthesis, Antigen Peptide, EBOV NP–derived peptide (NP44–52) YQVNNLEEI

Long-term cellular immunity of vaccines for Zaire Ebola Virus Diseases Wiedemann et al., Nature Communications (2024) - PMID: 39227399 Product used: PepMix™ Zaire Ebola (GP/Mayinga-76)

Characterizing changes in transcriptome and kinome responses in testicular cells during infection by Ebola virus Webb et al., Viruses (2024) Product used: Custom PepStar

Early Sertoli cell gene expression regulates pathogenesis in response to Ebola virus Webb et al., Research Square (2023) Product used: Custom PepStar

Single-dose YF17D-vectored Ebola vaccine candidate protects mice against both lethal surrogate Ebola and yellow fever virus challenge Lemmens et al., Vaccines (2023) Products used: PepMix™ Zaire Ebola (GP/Kikwit-95) & PepMix™ Yellow fever (NS4B)

A novel intradermal tattoo-based injection device enhances the immunogenicity of plasmid DNA vaccines Gomez et al., Vaccines (2022) - PMID: 36543794 Products used: PepMix™ Zaire Ebola (GP/Mayinga-76)

Ebola Vaccine-induced Protection in Non-human Primates correlates with Antibody Specificity and Fc-mediated Effects Meyer et al., SciTranslMed (2021) - PMID: 34261800

Recombinant Modified Vaccinia Virus Ankara Generating Ebola Virus-Like Particles Schweneker et al., Journal of Virology (2017) - PMID: 28331098

Antibody Quality and Protection from Lethal Ebola Virus Challenge in Nonhuman Primates Immunized with Rabies Virus Based Bivalent Vaccine Blaney et al., PLOS Pathogens (2013) - PMID: 2373747

Application Notes

The Challenge of Antigen Sequence Diversity: Solutions with ULTRA-Peptide LibrariesU. Reimer et al., Application Note (2016)

A Modular Approach for Epitope Discovery and High-Resolution Profiling of Humoral Immune ResponsesN. Pawlowski, J. Jansong, J. Zerweck, U. Reimer, Application Note (2013)

Qualification and Use of Peptide Libraries for Clinical Trial ImmunomonitoringJ. H. Cox & P. Hayes, Application Note (2013)

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

Related questions

01What If You Combined Multiple Peptides — Would That Amplify Telomere Benefits?

Stacking Thymalin (immune modulation) with MK-677 (mitochondrial support) targets two independent pathways tied to telomere stability. Immune cell turnover and oxidative damage reduction. There's no evidence they interfere with each other, and the mechanisms don't overlap. However, combining peptides increases the chance of side effects (MK-677's glucose elevation plus Thymalin's immune activation could theoretically exacerbate autoimmune flares in predisposed individuals) and complicates dosing schedules. Most gerontology research protocols isolate one intervention at a time to measure specific effects. Polypharmacy approaches make attribution of benefits or harms impossible. If you're designing a protocol that includes multiple compounds, consult researchers experienced in peptide interactions.

Source: realpeptides.co ↗
02What If My Fatigue Doesn't Improve After 8 Weeks on Mitochondrial-Targeting Peptides?

Assess concurrent nutrient deficiencies and hidden infections. Mitochondrial biogenesis requires cofactors: CoQ10 (for electron transport), magnesium (for ATP synthase function), B vitamins (for Krebs cycle enzymes), and iron (for Complex I assembly). If any are deficient, PGC-1α upregulation creates non-functional mitochondria. The structure is there, but the machinery doesn't work. Additionally, chronic infections (Epstein-Barr reactivation, Lyme, Bartonella) independently suppress mitochondrial function through immune-mediated oxidative stress. Research in the Journal of Translational Medicine (2019) found that unresolved Lyme infection reduced mitochondrial membrane potential by 30% regardless of mycotoxin status. Rule out both before concluding the peptide protocol failed.

Source: realpeptides.co ↗
03What If I Stack Multiple Peptides (BPC-157, TB-4, NAC) — Does That Increase Efficacy?

Stacking doesn't bypass the fundamental pharmacokinetic limitations. Each peptide has a distinct clearance timeline and mechanism. Combining them doesn't extend their effective window during the hangover phase. NAC at therapeutic doses (1,200–1,800mg orally) has the strongest evidence base for supporting glutathione synthesis, but even NAC requires sustained dosing to shift baseline levels. A multi-peptide stack administered hours before drinking doesn't create additive benefit if each individual compound is cleared before acetaldehyde metabolism peaks.

Source: realpeptides.co ↗
04What If I Experience Injection Site Reactions?

Rotate injection sites across at least four anatomical zones (lower abdomen left/right, lateral thighs left/right) and allow 72 hours between injections in the same site. Persistent erythema or induration lasting >48 hours may indicate preservative sensitivity to benzyl alcohol in bacteriostatic water. Switch to sterile water for injection and prepare fresh doses every 3–5 days instead of using a multi-dose vial. If reactions continue, subcutaneous administration may not be tolerable; consider oral peptide formulations (lower bioavailability but viable for maintenance dosing) or discuss intramuscular alternatives like Cerebrolysin, which uses a different vehicle and injection depth.

Source: realpeptides.co ↗
05What If I Use DSIP During My Night Shift to Stay Alert?

Do not use DSIP during wakefulness windows. It induces delta-wave sleep within 30–45 minutes of administration and will impair alertness for 4–6 hours. DSIP is exclusively a post-shift intervention for daytime sleep induction. If you need wakefulness support during night shifts, Semax at 300–600 mcg intranasal provides cognitive support without sedation, but it's not a stimulant and won't override severe sleep deprivation.

Source: realpeptides.co ↗
comparison

Peptides for Panic Disorder Protocol Evidence Guide: Comparison

Cerebrolysin BDNF upregulation, synaptic plasticity enhancement Accelerates fear extinction 40–60% in conditioned fear models (rodent) Open-label trials in PTSD show 34% symptom reduction; …

Source: realpeptides.co
comparison

Peptides for Heavy Metal Chelation — Protocol Comparison

Mechanism of Action Multidentate coordination with stable metal complexes; facilitates renal excretion Antioxidant buffering; indirect support of Phase II detox pathways Endogenous inductio…

Source: realpeptides.co
comparison

Peptides for Insomnia Chronic Protocol: Evidence Comparison

DSIP GABA-A receptor modulation, increased chloride conductance 25–50mcg subcutaneous 60–90 min before sleep Sleep latency reduction within 3–7 days Moderate. Multiple small RCTs, limited r…

Source: realpeptides.co
Research context

Read sources and limitations before applying a claim.

Compliance and Research Context

The peptides discussed in this article. BPC-157, TB-500, and GHK-Cu. Are sold by various suppliers as research-grade compounds for laboratory use only. At Real Peptides, every peptide undergoes small-batch synthesis with exact amino-acid sequencing, third-party purity verification, and sterility testing to ensure lab-grade reliability. The compounds are not sold as drugs, and no claims are made regarding human therapeutic use. Researchers integrating these peptides into preclinical wound healing models can explore offerings like Thymalin or KPV 5MG, which demonstrate immunomodulatory and anti-inflammatory properties relevant to tissue repair pathways. All peptide information in this guide is derived from peer-reviewed preclinical studies. It is for educational purposes and does not constitute medical advice. Burn treatment decisions should be made in consultation with a licensed medical professional specializing in wound care or burn surgery. The most overlooked detail in peptide research for burn healing isn't efficacy. It's delivery method. Peptides are proteins, and proteins degrade rapidly in the acidic, protease-rich environment of an open wound. Topical application without a protective vehicle (liposomal encapsulation, hydrogel matrix) reduces bioavailability by 60–80%. That's why systemic administration (subcutaneous injection) consistently outperforms topical application in deep burn models for BPC-157 and TB-500. If the peptide never reaches viable tissue in therapeutic concentrations, the mechanism doesn't matter. Most research protocols overlook this. They assume delivery, then wonder why results don't replicate.

Source: realpeptides.co ↗

Clinical Trial Immune Monitoring & Cell Therapy

High quality chemically synthesized antigen source for vaccine trial monitoring Ancillary reagents for cellular therapy development Full analytical coverage, stability testing, batch documentation and more

Source: jpt.com ↗
Practical and safety references

These excerpts are educational, not personalised medical instructions.

Dosage reference

Dosage Ranges, Administration Routes, and Bioavailability Constraints

BPC-157 has been studied at doses ranging from 10 mcg/kg to 500 mcg/kg in animal models, administered subcutaneously, intraperitoneally, or orally. Oral administration shows gastric stability. The peptide resists degradation by pepsin. But intestinal absorption rates vary. Subcutaneous injection bypasses first-pass degradation entirely. Most gastrointestinal research uses the 10 mcg/kg dose range for systemic effects. KPV is typically administered orally in colitis models at doses between 5–25 mg/kg. The tripeptide structure allows some gastric stability, but enteric coating improves delivery to the distal intestine where colitis-related permeability is most pronounced. Subcutaneous KPV has been used in dermatological wound healing studies, but oral administration is preferred for gastrointestinal applications. TB-500 dosing in research ranges from 5–20 mg per injection in larger animal models, administered subcutaneously twice weekly. TB-500's longer half-life (approximately 10 days) allows less frequent dosing than BPC-157. The peptide's mechanism. Actin polymerization and cytoskeletal remodeling. Requires time to manifest, so acute dosing doesn't produce the same rapid effects seen with BPC-157's junction stabilization. Bioavailability is the limiting factor for all three peptides. BPC-157 shows documented gastric stability, but intestinal peptidase activity still degrades a significant portion before systemic absorption. KPV's tripeptide structure makes it more susceptib…

Source: realpeptides.co ↗
Potential benefits

Immunomodulatory benefits of thymosin alpha

The many benefits of thymosin alpha make it arguably the best peptide for the immune system. It may fight off bacterial, viral, and fungal infections. It might also enhance nerve regeneration. The peptide’s immunomodulatory properties have been deployed against various viral diseases, including: Hepatitis B Hepatitis C AIDS Pseudomonas Sepsis

Source: livvnatural.com ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →

Continue learning

Related guides

01
Peptide Therapy Guide Editorial Team

Visit the Whole Wide World of Peptide Pools

Visit the Whole Wide World of Peptide Pools Published on 18/01/2023 JPT has developed hundreds of innovative peptide products for addressing both humoral and cellular immunity. One of our most popular products…

Read guide →
02
Peptide Therapy Guide Editorial Team

This February: RSV Peptide Pools & Arrays 20% OFF

This February: RSV Peptide Pools & Arrays 20% OFF Published on 30/01/2023 Entering the second month of 2023 we announce a 20% discount on all our RSV catalog PepMix Peptide Pools and PepStar Peptide Microarray…

Read guide →